Swiss medical device developer CorFlow Therapeutics said today that it has raised $9.7 million in the second close of its seed+ financing round. The first round closed in October 2017 at $2.7 million (CHF 2.6 million).
The proceeds will finance the first-in-man clinical trial in Europe of the company’s controlled flow infusion (CoFITM) system, which will be studied in 40 acute heart attack patients. CorFlow said it has applied to conduct the trial in six leading cardiovascular centers in Switzerland, the U.K., Belgium and Germany.
Get the full story at our sister site, Medical Design & Outsourcing.
The post CorFlow raises $9.7 million to launch clinical trial in Europe appeared first on MassDevice.
from MassDevice https://ift.tt/2x4E8Kq
Cap comentari:
Publica un comentari a l'entrada